Brief: Kiniksa Pharmaceuticals Posts Q4 Product Revenue USD 39.939 Million
28/02/2023 13:28
Feb 28 (Reuters) - Kiniksa Pharmaceuticals * Q4 product revenue USD 39.939 million. * Q4 operating expenses USD 55.837 million * Q4 EPS USD 0.06 * Q4 pretax profit USD 6.841 million * Q4 net income USD 4.461 million
Recent news on Kiniksa Pharmaceuticals International
See all newsKiniksa Pharmaceuticals International, PLC reports results for the quarter ended June 30 - Earnings Summary
Kiniksa Pharmaceuticals Q2 product revenue rises on ARCALYST sales
Kiniksa Pharmaceuticals International, PLC expected to post earnings of 30 cents a share - Earnings Preview
Cardiovascular drugmaker Kiniksa's Q1 net income rises
Kiniksa Q4 revenue rises on ARCALYST sales